Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTG-CARCIK-CD19
- Development stage
- Unknown
- Lead developer
- University of Milano-Bicocca
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PTG-CARCIK-CD19 (also known as CMN-005) is an investigational, allogeneic, donor-derived chimeric antigen receptor (CAR) cytokine-induced killer (CIK) cell therapy targeting CD19. It is genetically engineered using the non-viral Sleeping Beauty transposon/transposase system (specifically the SB100X vector) to express a CD19-specific CAR containing CD28 and OX40 costimulatory domains and a CD3-zeta signaling domain. This non-viral manufacturing approach is designed to reduce the cost and logistical complexity associated with traditional viral vector-based CAR-T therapies. PTG-CARCIK-CD19 is being developed in collaboration by the University of Milano-Bicocca, Fondazione Tettamanti, and CoImmune (which merged with Formula Pharmaceuticals). It is currently in Phase I/II clinical trials for the treatment of B-cell malignancies, including B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL).
- Other names
- CARCIK-CD19CARCIK-CD-19CARCIK-CD 19CIK-CAR CD19CIK-CAR.CD19
02
Targets
Beyond the preview
Go deeper on PTG-CARCIK-CD19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTG-CARCIK-CD19.